Search
for
Sort by
Research 151–180 of 303
- A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- When JAK inhibitors are off the table: durable remission of severe alopecia areata with dexamethasone oral mini-pulse and a focused review
- Editor’s Picks June 2025
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Successful Remission of Alopecia Areata and Seborrheic Dermatitis in a 21-Year-Old Male via Functional Nutrition and Advanced Diagnostics: A Case Report.
- Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Phytochemicals and novel delivery systems in alopecia management: An integrative review
- Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- 52993 Regulatory γδ T cells protect human scalp hair follicles from alopecia areata in vivo
- A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis
- A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index
- Skin and Scalp Health Benefits of a Specific Botanical Extract Blend: Results from a Double-Blind Placebo-Controlled Study in Urban Outdoor Workers
- Chemotherapy-Induced Alopecia in Breast Cancer Patients: Treatment-Specific Incidence and Risk of Persistent Hair Loss
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata